{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:40:21Z","timestamp":1765888821190,"version":"3.41.2"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Global Oncology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> This study aims to describe the clinical manifestations, laboratory findings, treatment, and outcomes of patients with cancer with COVID-19 infection in Syria. The primary objective was to identify the overall survival (OS) time, and the secondary objectives were to identify factors associated with severe COVID-19 infection. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> This multicenter retrospective study was undertaken at four hospitals in Damascus, Syria, between March 28, 2020, and March 29, 2021. Data extracted from medical records included clinical manifestations, radiologic findings, laboratory results, treatment, and outcomes. Survival analysis was done by using the Kaplan-Meier method and Cox regression model for follow-up and anticancer treatment patients to study the effect on OS time. The effects of potential risk factors of developing severe COVID-19 were studied by multivariable logistic regression. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Of 114 patients included, 61 (53.51%) were male. Smokers represented 29 (25.44%), and 63 (55.26%) patients had a history of coexisting chronic diseases. The most common cancer type was breast cancer 17 (14.91%). Sixty-eight (59.65%) patients were receiving anticancer treatment within 1 month of being diagnosed with COVID-19 infection and 46 (40.35%) were outpatient follow-ups. Multiple logistic regression analysis showed that comorbidities (odds ratio: 2.814, P = .044) and anticancer treatment (odds ratio: 8.790, P &lt; .05) were risk factors linked to severe to critical COVID-19 infection. OS time was 245 (95% CI, 217.96 to 272.47) days, lower among patients with cancer with COVID-19 infection receiving anticancer treatment compared with follow-up patients ( P value &lt; .05). <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Patients with cancer with COVID-19 infection receiving anticancer treatment had a lower OS time. It may be worth considering stopping anticancer treatment in patients with cancer with COVID-19 when possible in search of better outcomes. <\/jats:p><\/jats:sec>","DOI":"10.1200\/go.21.00283","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T20:59:16Z","timestamp":1646168356000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 Disease in Syrian Patients With Cancer: Clinical Manifestations, Laboratory Findings, Treatment, and Outcomes"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-3112","authenticated-orcid":false,"given":"Michel","family":"Najjar","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Syrian Private University, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Albuaini","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Syrian Private University, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Fadel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Syrian Private University, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Aljbawi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Syrian Private University, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3472-6099","authenticated-orcid":false,"given":"Fatema","family":"Mohsen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Syrian Private University, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seham","family":"Sulaiman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Damascus University, Damascus, Syria"},{"name":"Department of Internal Medicine, Faculty of Medicine, Syrian Private University, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abir","family":"Koudsi","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Faculty of Medicine, Damascus University, Damascus, Syria"},{"name":"Department of Family and Community Medicine, Faculty of Medicine, Syrian Private University, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"volume-title":"Reported Cases and Deaths by Country or Territory","year":"2021","author":"worldometer","key":"b1"},{"volume-title":"Total Coronavirus Cases in Syria","year":"2021","author":"worldometer","key":"b2"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6178"},{"volume-title":"COVID-19 Vaccines in People With Cancer","year":"2021","author":"American Cancer Society","key":"b4"},{"volume-title":"WHO COVID-19 Case Definition","year":"2020","author":"WHO","key":"b5"},{"volume-title":"Diagnostic Testing for SARS-CoV-2","year":"2020","author":"WHO","key":"b6"},{"volume-title":"Clinical Spectrum of SARS-CoV-2 Infection","year":"2021","author":"COVID-19 Treatment Guidelines","key":"b7"},{"volume-title":"COVID-19 Clinical Management: Living Guidance","year":"2021","author":"WHO","key":"b8"},{"volume-title":"Cancer Staging","year":"2020","author":"American Cancer Society","key":"b9"},{"volume-title":"Syria: iMMAP\/DFS COVID-19 Situation Analysis (20 October-22 November 2020)","year":"2021","author":"relifeweb","key":"b10"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22474-9"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100418"},{"volume-title":"Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers","year":"2021","author":"Centers for Disease Control and Prevention","key":"b13"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3692"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33042"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01307"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000463"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25972"},{"key":"b19","first-page":"361","volume":"13","author":"Mousavi-Nasab SD","year":"2020","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.06.017"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.04.043"},{"volume-title":"How Does Coronavirus Kill? Clinicians Trace a Ferocious Rampage Through the Body, From Brain to Toes","year":"2020","author":"Science","key":"b22"},{"volume-title":"Therapeutic Management of Hospitalized Adults With COVID-19","year":"2021","author":"COVID-19 Treatment Guidelines","key":"b23"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.101989"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000806"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.06.004"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201706-1172OC"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.09.008"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.07.006"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"volume-title":"Updated CCC19 Data Offer Insights on Treatment for Patients With Cancer and COVID-19 Infection","year":"2020","author":"The ASCO Post","key":"b32"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO.21.00283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:03:58Z","timestamp":1653822238000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO.21.00283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1200\/GO.21.00283"],"URL":"https:\/\/doi.org\/10.1200\/go.21.00283","relation":{},"ISSN":["2687-8941"],"issn-type":[{"type":"electronic","value":"2687-8941"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2021-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2100283"}}